Truvada

Drugbox
type = combo
component1 = Tenofovir
class1 = Nucleotide analogue reverse transcriptase inhibitor
component2 = Emtricitabine
class2 = Nucleoside reverse transcriptase inhibitor
CAS_number =
ATC_prefix = J05
ATC_suffix = AR03
PubChem = 11954236
DrugBank =
pregnancy_AU =
pregnancy_US = B
pregnancy_category=
legal_AU =
legal_CA =
legal_UK = POM
legal_US = Rx-only
legal_status =
routes_of_administration = Oral

Truvada is a fixed dose combination of two antiretroviral drugs used for the treatment of HIV. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine. By combining the two agents into one tablet, it reduces the pill burden and increases compliance with antiretroviral therapy. The drug has also found some potential as a preventative measure if taken before sex, though human clinical trials are ongoing [http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2006/03/27/national/a145047S06.DTL] .

Truvada was developed by Gilead Sciences and approved by the Untited States' Food and Drug Administration in 2004.

A combination pill containing Truvada and efavirenz (Sustiva) is also available and is marketed as Atripla.

External links

* [http://www.truvada.com Truvada website] , run by Gilead Sciences